Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:salicylamides
go back to main search page
Accession:CHEBI:53443 term browser browse the term


show annotations for term's descendants           Sort by:
 
3,3',4',5-tetrachlorosalicylanilide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Atf3 activating transcription factor 3 increases expression ISO 3,3',4',5-tetrachlorosalicylanilide results in increased expression of ATF3 mRNA CTD PMID:27965148 NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
JBrowse link
G Dnajb4 DnaJ heat shock protein family (Hsp40) member B4 increases expression ISO 3,3',4',5-tetrachlorosalicylanilide results in increased expression of DNAJB4 mRNA CTD PMID:27965148 NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089
JBrowse link
G Iyd iodotyrosine deiodinase multiple interactions ISO 3,3',4',5-tetrachlorosalicylanilide inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] CTD PMID:33352258 NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319
JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO 3,3',4',5-tetrachlorosalicylanilide inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
JBrowse link
3,5-dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Agt angiotensinogen multiple interactions ISO Clozapine promotes the reaction [Raclopride promotes the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]]; Raclopride inhibits the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]; Raclopride promotes the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]] CTD PMID:11549694 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Calca calcitonin-related polypeptide alpha multiple interactions EXP Raclopride inhibits the reaction [Dextroamphetamine results in increased expression of CALCA protein] CTD PMID:11398184 NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
JBrowse link
G Camk4 calcium/calmodulin-dependent protein kinase IV decreases expression EXP Raclopride results in decreased expression of CAMK4 protein CTD PMID:19289156 NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487
JBrowse link
G Camkk1 calcium/calmodulin-dependent protein kinase kinase 1 decreases expression EXP Raclopride results in decreased expression of CAMKK1 protein CTD PMID:19289156 NCBI chr10:57,637,335...57,660,498
Ensembl chr10:57,637,391...57,660,498
JBrowse link
G Camkk2 calcium/calmodulin-dependent protein kinase kinase 2 decreases expression EXP Raclopride results in decreased expression of CAMKK2 protein CTD PMID:19289156 NCBI chr12:33,791,023...33,845,000
Ensembl chr12:33,791,052...33,843,279
JBrowse link
G Crh corticotropin releasing hormone decreases expression ISO Raclopride results in decreased expression of CRH mRNA CTD PMID:16205782 NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions
increases expression
EXP DRD2 protein affects the reaction [Raclopride results in increased expression of CTNNB1 protein] CTD PMID:16144542 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
JBrowse link
G Drd1 dopamine receptor D1 multiple interactions ISO Raclopride inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole] CTD PMID:8103921 NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
JBrowse link
G Drd2 dopamine receptor D2 multiple interactions
affects binding
increases response to substance
ISO
EXP
[Dopamine co-treated with Raclopride] promotes the reaction [Dopamine binds to DRD2 protein]; Cocaine affects the reaction [Raclopride binds to DRD2]
Raclopride binds to DRD2 protein
[Raclopride binds to and results in decreased activity of DRD2 protein] which results in decreased susceptibility to Methylphenidate; [Raclopride binds to and results in decreased activity of DRD2 protein] which results in decreased susceptibility to Nicotine; [Raclopride binds to and results in decreased activity of DRD2 protein] which results in increased abundance of Dopamine; DRD2 protein affects the reaction [Raclopride results in increased expression of CTNNB1 protein]; DRD2 protein affects the reaction [Raclopride results in increased expression of GSK3A protein]; Raclopride binds to and results in decreased activity of DRD2 protein; Saponins inhibits the reaction [Raclopride binds to DRD2 protein]
Amlodipine inhibits the reaction [Raclopride binds to DRD2 protein]; bisphenol A promotes the reaction [Raclopride binds to DRD2 protein]; Diltiazem inhibits the reaction [Raclopride binds to DRD2 protein]; Flunarizine inhibits the reaction [Raclopride binds to DRD2 protein]; manidipine inhibits the reaction [Raclopride binds to DRD2 protein]; Raclopride inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole]; Verapamil inhibits the reaction [Raclopride binds to DRD2 protein]
Raclopride binds to DRD2 protein; Raclopride binds to DRD2 protein alternative form
DRD2 protein alternative form results in increased susceptibility to Raclopride
Raclopride binds to DRD2; Raclopride binds to DRD2 protein
CTD PMID:1833784 PMID:7901417 PMID:8103921 PMID:8804920 PMID:9533112 More... NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
JBrowse link
G Drd3 dopamine receptor D3 multiple interactions EXP [Raclopride binds to and results in decreased activity of DRD3 protein] which results in increased abundance of Dopamine; Raclopride binds to and results in decreased activity of DRD3 protein CTD PMID:15341276 PMID:19289156 NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
JBrowse link
G Fadd Fas associated via death domain multiple interactions EXP Raclopride affects the reaction [Cocaine affects the expression of FADD protein] CTD PMID:18580876 NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit increases expression EXP Raclopride results in increased expression of FOS protein CTD PMID:17913375 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions ISO Raclopride inhibits the reaction [Methamphetamine results in increased expression of GFAP protein] CTD PMID:16088948 NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
JBrowse link
G Gsk3a glycogen synthase kinase 3 alpha multiple interactions
increases expression
EXP DRD2 protein affects the reaction [Raclopride results in increased expression of GSK3A protein] CTD PMID:16144542 NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO Raclopride inhibits the reaction [Dronabinol results in increased activity of MAPK1 protein] CTD PMID:11553284 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO Raclopride inhibits the reaction [Dronabinol results in increased activity of MAPK3 protein] CTD PMID:11553284 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 affects response to substance ISO NR4A1 affects the susceptibility to Raclopride CTD PMID:14603264 NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
JBrowse link
G Plat plasminogen activator, tissue type multiple interactions ISO Raclopride inhibits the reaction [Methamphetamine results in increased expression of PLAT mRNA] CTD PMID:15659235 NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
JBrowse link
G Ppp1r1b protein phosphatase 1, regulatory (inhibitor) subunit 1B increases phosphorylation ISO Raclopride results in increased phosphorylation of PPP1R1B protein CTD PMID:12064480 NCBI chr10:83,347,731...83,356,775
Ensembl chr10:83,347,731...83,356,775
JBrowse link
G Rgs2 regulator of G-protein signaling 2 multiple interactions
increases expression
EXP Raclopride promotes the reaction [Amphetamine results in increased expression of RGS2 mRNA]
Raclopride results in increased expression of RGS2 mRNA
CTD PMID:10098858 NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
JBrowse link
G Th tyrosine hydroxylase multiple interactions ISO Raclopride inhibits the reaction [Methamphetamine results in decreased expression of TH protein] CTD PMID:16088948 NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
JBrowse link
acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc1 ATP binding cassette subfamily C member 1 affects response to substance ISO ABCC1 gene SNP affects the susceptibility to nitazoxanide CTD PMID:25622337 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
JBrowse link
G Ar androgen receptor multiple interactions ISO nitazoxanide binds to and results in decreased activity of AR protein CTD PMID:25752796 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions
increases expression
ISO nitazoxanide promotes the reaction [EIF2A protein results in increased expression of ATF4 protein]
nitazoxanide results in increased expression of ATF4 protein
CTD PMID:19664635 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
JBrowse link
G Dock8 dedicator of cytokinesis 8 affects response to substance ISO DOCK8 gene SNP affects the susceptibility to nitazoxanide CTD PMID:25622337 NCBI chr 1:222,649,309...222,842,474
Ensembl chr 1:222,649,309...222,842,474
JBrowse link
G Eif2a eukaryotic translation initiation factor 2A multiple interactions
increases phosphorylation
ISO IFNA2 protein promotes the reaction [nitazoxanide results in increased phosphorylation of EIF2A protein]; nitazoxanide promotes the reaction [EIF2A protein results in increased expression of ATF4 protein]; nitazoxanide promotes the reaction [EIF2AK2 protein results in increased phosphorylation of EIF2A protein] CTD PMID:19664635 NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068
JBrowse link
G Eif2ak2 eukaryotic translation initiation factor 2-alpha kinase 2 multiple interactions ISO IFNA2 protein promotes the reaction [nitazoxanide promotes the reaction [EIF2AK2 protein results in increased phosphorylation of and results in increased activity of EIF2AK2 protein]]; nitazoxanide promotes the reaction [EIF2AK2 protein results in increased phosphorylation of and results in increased activity of EIF2AK2 protein]; nitazoxanide promotes the reaction [EIF2AK2 protein results in increased phosphorylation of EIF2A protein] CTD PMID:19664635 NCBI chr 6:16,189,000...16,224,972
Ensembl chr 6:16,188,979...16,224,971
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases activity ISO nitazoxanide results in increased activity of NR1I3 protein CTD PMID:30247703 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
JBrowse link
G Slit3 slit guidance ligand 3 affects response to substance ISO SLIT3 gene SNP affects the susceptibility to nitazoxanide CTD PMID:25622337 NCBI chr10:19,571,798...20,156,634
Ensembl chr10:19,571,684...20,156,634
JBrowse link
G Susd6 sushi domain containing 6 affects response to substance ISO SUSD6 gene SNP affects the susceptibility to nitazoxanide CTD PMID:25622337 NCBI chr 6:100,437,826...100,531,621
Ensembl chr 6:100,437,642...100,531,606
JBrowse link
labetalol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb4 ATP binding cassette subfamily B member 4 decreases activity ISO Labetalol results in decreased activity of ABCB4 protein CTD PMID:28437613 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
JBrowse link
G Ace2 angiotensin I converting enzyme 2 increases activity ISO Labetalol results in increased activity of ACE2 protein CTD PMID:21859683 NCBI chr  X:30,293,597...30,340,961
Ensembl chr  X:30,293,589...30,340,977
JBrowse link
G Adrb1 adrenoceptor beta 1 decreases activity
affects binding
increases activity
multiple interactions
ISO
EXP
Labetalol results in decreased activity of ADRB1 protein
Labetalol binds to ADRB1 protein
Labetalol results in increased activity of ADRB1 protein
[Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP; CGP 20712A inhibits the reaction [[Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [Labetalol results in increased activity of ADRB1 protein]
Labetalol binds to and results in decreased activity of ADRB1 protein; Labetalol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Labetalol inhibits the reaction [Dihydroalprenolol binds to ADRB1 protein]
CTD PMID:2462161 PMID:2567112 PMID:11425575 PMID:11483288 PMID:12761341 NCBI chr 1:255,772,217...255,773,617
Ensembl chr 1:255,771,597...255,807,259
JBrowse link
G Adrb2 adrenoceptor beta 2 decreases activity
affects binding
multiple interactions
ISO
EXP
Labetalol results in decreased activity of ADRB2 protein
Labetalol binds to ADRB2 protein
[Labetalol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Labetalol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Labetalol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein
Labetalol binds to and results in decreased activity of ADRB2 protein; Labetalol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Labetalol inhibits the reaction [Dihydroalprenolol binds to ADRB2 protein]
CTD PMID:2462161 PMID:2567112 PMID:11425575 PMID:11483288 PMID:17925438 NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
JBrowse link
G Agt angiotensinogen decreases expression ISO Labetalol results in decreased expression of AGT protein CTD PMID:14627 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Avp arginine vasopressin multiple interactions ISO [Labetalol co-treated with Isoflurane] results in increased expression of AVP protein CTD PMID:1897344 NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO [Labetalol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein CTD PMID:17925438 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO [Labetalol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein CTD PMID:17925438 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Nppa natriuretic peptide A decreases activity ISO Labetalol results in decreased activity of NPPA protein CTD PMID:2524958 NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
JBrowse link
G Prl prolactin multiple interactions
increases expression
ISO carbidopa, levodopa drug combination inhibits the reaction [Labetalol results in increased expression of PRL protein] CTD PMID:7105431 NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
JBrowse link
G Ren renin multiple interactions
decreases activity
ISO [Labetalol co-treated with Isoflurane] results in increased expression of REN protein
Labetalol results in decreased activity of REN protein
CTD PMID:1897344 PMID:2524958 PMID:7013770 PMID:7988622 NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 multiple interactions ISO [Uridine Diphosphate Glucuronic Acid co-treated with UGT1A1 protein] results in increased glucuronidation of Labetalol CTD PMID:18098064 NCBI chr 9:88,801,344...88,808,465 JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 multiple interactions ISO [Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased glucuronidation of Labetalol; Fluconazole inhibits the reaction [[Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased glucuronidation of Labetalol] CTD PMID:18098064 NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
JBrowse link
salicylamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor multiple interactions ISO salicylamide inhibits the reaction [Tetrachlorodibenzodioxin binds to and results in increased activity of AHR protein] CTD PMID:14729655 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO salicylamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
salicylamide inhibits the reaction [carbendazim results in increased expression of CYP1A1 protein]
CTD PMID:14729655 PMID:27286660 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO salicylamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA] CTD PMID:14729655 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions ISO salicylamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA] CTD PMID:14729655 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO [salicylamide co-treated with Glucose] binds to PPARA protein; salicylamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]] CTD PMID:18812576 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 multiple interactions ISO
EXP
Mefenamic Acid inhibits the reaction [SULT1A1 protein results in increased sulfation of salicylamide] CTD PMID:11181495 NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
JBrowse link
tribromosalicylanilide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Iyd iodotyrosine deiodinase multiple interactions ISO tribromsalan inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] CTD PMID:33352258 NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19821
    role 19769
      biological role 19769
        antimicrobial agent 17408
          antifungal agent 15099
            salicylic acid 769
              salicylamides 50
                2,3-dihydroxy-5-\{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl\}benzamide 0
                2,4-dihydroxy-N-[[4-methoxy-3-[(2-pyridinylthio)methyl]phenyl]methylideneamino]benzamide 0
                2-hydroxy-5-[1-hydroxy-2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzamide 0
                2-hydroxy-5-\{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl\}benzamide + 13
                2-hydroxy-N'-[(5-hydroxy-6-oxo-1-cyclohexa-2,4-dienylidene)methyl]benzohydrazide 0
                2-hydroxy-N'-[(6-oxo-1-cyclohexa-2,4-dienylidene)methyl]benzohydrazide 0
                2-hydroxy-N'-[[2,4,6-trioxo-1-(2-phenylethyl)-1,3-diazinan-5-ylidene]methyl]benzohydrazide 0
                2-hydroxy-N-[(1-methyl-2-oxo-3-indolylidene)amino]benzamide 0
                2-hydroxy-N-[(3-hydroxyphenyl)methylideneamino]benzamide 0
                2-hydroxy-N-[1-(5-nitro-2-tetrazolyl)propan-2-ylideneamino]benzamide 0
                2-hydroxy-N-[[5-(3-nitrophenyl)-2-furanyl]methylideneamino]benzamide 0
                3,5-dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide 21
                3-(2-furanyl)-2-propenoic acid [3-bromo-5-[[[(2-hydroxyphenyl)-oxomethyl]hydrazinylidene]methyl]phenyl] ester 0
                5-bromo-2-hydroxy-N-(1-thiophen-2-ylethylideneamino)benzamide 0
                5-chloro-3-ethyl-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide 0
                5-chloro-N-[4-(2-furanyl)but-3-en-2-ylideneamino]-2-hydroxybenzamide 0
                Acotiamide 0
                Desacetyl-nitazoxanide 0
                LSM-31220 0
                Labetalol hydrochloride 0
                Myxochelin A 0
                Myxochlin A 0
                Myxochlin C 0
                N'-[(3,5-dibromo-6-oxo-1-cyclohexa-2,4-dienylidene)methyl]-2-hydroxybenzohydrazide 0
                N'-[(3,5-dichloro-6-oxo-1-cyclohexa-2,4-dienylidene)methyl]-2-hydroxybenzohydrazide 0
                N'-[(4-chlorophenyl)-oxomethyl]-2-hydroxy-3-methylbenzohydrazide 0
                N-(1-cyclohex-3-enylmethylideneamino)-2,4-dihydroxybenzamide 0
                N-[(2-hydroxyphenyl)-oxomethyl]-2,3-dihydrobenzofuran-5-carboxamide 0
                N-[[4-(2-anilino-2-oxoethoxy)phenyl]methylideneamino]-2-hydroxybenzamide 0
                N-[[6-[2-[acetyl(methyl)amino]ethyl]-4-methoxy-1,3-benzodioxol-5-yl]methylideneamino]-2-hydroxybenzamide 0
                N-[[[(2-hydroxyphenyl)-oxomethyl]hydrazo]-sulfanylidenemethyl]-2-nitrobenzamide 0
                Sultopride 0
                Trichlamide 0
                alibendol 0
                buclosamide 0
                medroxalol 0
                salacetamide 0
                salicylamide + 19
                salicylanilide + 4
Path 2
Term Annotations click to browse term
  CHEBI ontology 19821
    subatomic particle 19819
      composite particle 19819
        hadron 19819
          baryon 19819
            nucleon 19819
              atomic nucleus 19819
                atom 19819
                  main group element atom 19716
                    p-block element atom 19716
                      carbon group element atom 19640
                        carbon atom 19630
                          organic molecular entity 19630
                            organic group 18737
                              organic divalent group 18728
                                organodiyl group 18728
                                  carbonyl group 18675
                                    carbonyl compound 18675
                                      carboxylic acid 18373
                                        carboacyl group 17485
                                          univalent carboacyl group 17485
                                            carbamoyl group 17299
                                              carboxamide 17299
                                                monocarboxylic acid amide 15008
                                                  arenecarboxamide 7262
                                                    benzamides 7262
                                                      salicylamides 50
                                                        2,3-dihydroxy-5-\{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl\}benzamide 0
                                                        2,4-dihydroxy-N-[[4-methoxy-3-[(2-pyridinylthio)methyl]phenyl]methylideneamino]benzamide 0
                                                        2-hydroxy-5-[1-hydroxy-2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzamide 0
                                                        2-hydroxy-5-\{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl\}benzamide + 13
                                                        2-hydroxy-N'-[(5-hydroxy-6-oxo-1-cyclohexa-2,4-dienylidene)methyl]benzohydrazide 0
                                                        2-hydroxy-N'-[(6-oxo-1-cyclohexa-2,4-dienylidene)methyl]benzohydrazide 0
                                                        2-hydroxy-N'-[[2,4,6-trioxo-1-(2-phenylethyl)-1,3-diazinan-5-ylidene]methyl]benzohydrazide 0
                                                        2-hydroxy-N-[(1-methyl-2-oxo-3-indolylidene)amino]benzamide 0
                                                        2-hydroxy-N-[(3-hydroxyphenyl)methylideneamino]benzamide 0
                                                        2-hydroxy-N-[1-(5-nitro-2-tetrazolyl)propan-2-ylideneamino]benzamide 0
                                                        2-hydroxy-N-[[5-(3-nitrophenyl)-2-furanyl]methylideneamino]benzamide 0
                                                        3,5-dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide 21
                                                        3-(2-furanyl)-2-propenoic acid [3-bromo-5-[[[(2-hydroxyphenyl)-oxomethyl]hydrazinylidene]methyl]phenyl] ester 0
                                                        5-bromo-2-hydroxy-N-(1-thiophen-2-ylethylideneamino)benzamide 0
                                                        5-chloro-3-ethyl-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide 0
                                                        5-chloro-N-[4-(2-furanyl)but-3-en-2-ylideneamino]-2-hydroxybenzamide 0
                                                        Acotiamide 0
                                                        Desacetyl-nitazoxanide 0
                                                        LSM-31220 0
                                                        Labetalol hydrochloride 0
                                                        Myxochelin A 0
                                                        Myxochlin A 0
                                                        Myxochlin C 0
                                                        N'-[(3,5-dibromo-6-oxo-1-cyclohexa-2,4-dienylidene)methyl]-2-hydroxybenzohydrazide 0
                                                        N'-[(3,5-dichloro-6-oxo-1-cyclohexa-2,4-dienylidene)methyl]-2-hydroxybenzohydrazide 0
                                                        N'-[(4-chlorophenyl)-oxomethyl]-2-hydroxy-3-methylbenzohydrazide 0
                                                        N-(1-cyclohex-3-enylmethylideneamino)-2,4-dihydroxybenzamide 0
                                                        N-[(2-hydroxyphenyl)-oxomethyl]-2,3-dihydrobenzofuran-5-carboxamide 0
                                                        N-[[4-(2-anilino-2-oxoethoxy)phenyl]methylideneamino]-2-hydroxybenzamide 0
                                                        N-[[6-[2-[acetyl(methyl)amino]ethyl]-4-methoxy-1,3-benzodioxol-5-yl]methylideneamino]-2-hydroxybenzamide 0
                                                        N-[[[(2-hydroxyphenyl)-oxomethyl]hydrazo]-sulfanylidenemethyl]-2-nitrobenzamide 0
                                                        Sultopride 0
                                                        Trichlamide 0
                                                        alibendol 0
                                                        buclosamide 0
                                                        medroxalol 0
                                                        salacetamide 0
                                                        salicylamide + 19
                                                        salicylanilide + 4
paths to the root